160 related articles for article (PubMed ID: 31096781)
1. Corneal sterile infiltration induced by topical use of ocular hypotensive agent.
Manabe Y; Sawada A; Mochizuki K
Eur J Ophthalmol; 2020 Sep; 30(5):NP23-NP25. PubMed ID: 31096781
[TBL] [Abstract][Full Text] [Related]
2. Severe Corneal Disorders Developed After Brimonidine Tartrate Ophthalmic Solution Use.
Maruyama Y; Ikeda Y; Yokoi N; Mori K; Kato H; Ueno M; Kinoshita S; Sotozono C
Cornea; 2017 Dec; 36(12):1567-1569. PubMed ID: 28938378
[TBL] [Abstract][Full Text] [Related]
3. Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate.
Kasuya Y; Sano I; Makino S; Kawashima H
Case Rep Ophthalmol Med; 2020; 2020():4803651. PubMed ID: 32547800
[TBL] [Abstract][Full Text] [Related]
4. A case of bilateral deep stromal corneal opacity and vascularization after use of multiple antiglaucoma medications including brimonidine tartrate ophthalmic solution.
Tsujinaka A; Takai Y; Inoue Y; Tanito M
Acta Ophthalmol; 2019 Sep; 97(6):e948-e949. PubMed ID: 30609169
[No Abstract] [Full Text] [Related]
5. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation.
Lusthaus JA; Goldberg I
Expert Opin Drug Saf; 2017 Sep; 16(9):1071-1078. PubMed ID: 28656780
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study.
Jin SW; Lee SM
J Ocul Pharmacol Ther; 2018 Apr; 34(3):274-279. PubMed ID: 29297751
[TBL] [Abstract][Full Text] [Related]
7. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
8. A Case of Sterile Corneal Stromal Infiltration with Hypotonic Maculopathy Under Brimonidine Treatment.
Vidal Oliver L; Díaz Barrón A; López Montero A; Gil-Hernández I; Duch Samper AM
Ocul Immunol Inflamm; 2023 Oct; 31(8):1716-1719. PubMed ID: 35708458
[TBL] [Abstract][Full Text] [Related]
9. Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma.
Lee SM; Lee JE; Kim SI; Jung JH; Shin J
Indian J Ophthalmol; 2019 Aug; 67(8):1297-1302. PubMed ID: 31332113
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo corneal effects of latanoprost combined with brimonidine, timolol, dorzolamide, or brinzolamide.
Fukuda M; Takeda N; Shibata S; Shibata N; Shibata T; Sugiyama K; Sasaki H
Eur J Pharmacol; 2016 Sep; 787():43-6. PubMed ID: 27181069
[TBL] [Abstract][Full Text] [Related]
11. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%.
Chan K; Testa M; McCluskey P
J Ocul Pharmacol Ther; 2007 Aug; 23(4):372-6. PubMed ID: 17803436
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
Gandolfi SA; Lim J; Sanseau AC; Parra Restrepo JC; Hamacher T
Adv Ther; 2014 Dec; 31(12):1213-27. PubMed ID: 25430900
[TBL] [Abstract][Full Text] [Related]
13. Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil
Belfort R; Paula JS; Lopes Silva MJ; Della Paolera M; Kim T; Chen MY; Goodkin ML
Clin Ther; 2020 Feb; 42(2):263-275. PubMed ID: 32089329
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
15. [Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers].
Carrasco Font C; Arias Puente A; García Sáenz MC; Villarejo Díaz-Maroto I
Arch Soc Esp Oftalmol; 2004 Apr; 79(4):163-8. PubMed ID: 15124072
[TBL] [Abstract][Full Text] [Related]
16. Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil.
Saito H; Kagami S; Mishima K; Mataki N; Fukushima A; Araie M
J Glaucoma; 2019 Apr; 28(4):289-293. PubMed ID: 30720574
[TBL] [Abstract][Full Text] [Related]
17. Acute bilateral diffuse corneal opacity in a child.
Wang TJ; Hsiao CH; Hu FR; Wang IJ; Hou YC
Cornea; 2007 Apr; 26(3):375-8. PubMed ID: 17413971
[TBL] [Abstract][Full Text] [Related]
18. Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye.
Carrasco MA; Schlaen BA; Zárate JO
Int Ophthalmol; 2013 Oct; 33(5):557-60. PubMed ID: 23224363
[TBL] [Abstract][Full Text] [Related]
19. Interstitial Keratitis with Lipid Keratopathy Mimicking Corneal Opacity Induced by Brimonidine Tartrate Eye Drops.
Kasuya Y; Sano I; Makino S
Klin Monbl Augenheilkd; 2020 Dec; 237(12):1466-1467. PubMed ID: 33285590
[No Abstract] [Full Text] [Related]
20. Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5% timolol in normal-tension glaucoma patients.
Kim JM; Kim TW; Kim CY; Kim HK; Park KH
Jpn J Ophthalmol; 2016 Jan; 60(1):20-6. PubMed ID: 26578422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
